Zelira Therapeutics Limited
Zelira Therapeutics Limited
Your view on ZLDAF
Overview
What the company does, where it operates, and who runs it.
About Zelira Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Oludare Odumosu
- Headquarters
- 101 St George's Terrace, Perth, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Oludare Odumosu
- Headquarters
- 101 St George's Terrace, Perth, WA, AU
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia.
It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.
The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes.
Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019.
Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Zelira Therapeutics Limited, and the rating behind it. ZLDAF last traded at $0.42; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Zelira Therapeutics Limited. Starting points for Zelira Therapeutics Limited: EPS -$0.32, beta 0.70 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Zelira Therapeutics Limited. Zelira Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Zelira Therapeutics Limited. Trailing twelve-month EPS for Zelira Therapeutics Limited stands at -$0.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Zelira Therapeutics Limited. Zelira Therapeutics Limited has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Zelira Therapeutics Limited valued side by side against its closest peers. Zelira Therapeutics Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Zelira Therapeutics Limited, and how their positions are changing. At a $5.0M market value, institutional positions materially move Zelira Therapeutics Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Zelira Therapeutics Limited executives and directors. Shares of Zelira Therapeutics Limited have traded between $0.20 and $0.42 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Zelira Therapeutics Limited. Zelira Therapeutics Limited is a $5.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Zelira Therapeutics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Zelira Therapeutics Limited. Coverage tracks Zelira Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.